All News - Eli Lilly and Company
WEBLilly's latest press releases, stories, news resources and more.
Lilly.com | Eli Lilly and Company
WEBINDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's …
News Release - Eli Lilly and Company
WEBFDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. Download PDF. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and ...
WEBSep 13, 2024 · Lilly is committed to setting new expectations for patients living with eczema and is working with insurers, health systems and providers to enable patient access to EBGLYSS. Through Lilly Support Services™ for EBGLYSS™, Lilly will offer a patient support program including co-pay assistance for eligible, commercially insured patients.
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug ... - CNN
WEBJun 11, 2024 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early ...
Lilly expands manufacturing footprint in Ireland with $1.8 billion ...
WEBINDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease.
Eli Lilly and Company (LLY) Latest Stock News & Headlines
WEBGet the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.
Alzheimer's drug donanemab shows positive results, Eli Lilly ... - CNBC
WEBJul 17, 2023 · Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8, 2023 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
Next-generation drug from Eli Lilly boosts weight loss to 24% ... - CNN
WEBJun 26, 2023 · Eli Lilly’s Mounjaro, cleared for type 2 diabetes and awaiting FDA approval for weight loss, targets both GLP-1 and a hormone called GIP, and has produced weight loss of 21 to 23%.